The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.
 
Ding-Wei Ye
No Relationships to Disclose
 
Chengyuan Gu
No Relationships to Disclose
 
Lixin Hua
No Relationships to Disclose
 
Ranlu Liu
No Relationships to Disclose
 
Jun Li
No Relationships to Disclose
 
Mingxing Qiu
No Relationships to Disclose
 
Jianming Guo
No Relationships to Disclose
 
Haiying Dong
No Relationships to Disclose
 
Zhigang Ji
No Relationships to Disclose
 
Hong Guo
Employment - Hinova Pharmaceuticals
Leadership - Hinova Pharmaceuticals
Stock and Other Ownership Interests - Hinova Pharmaceuticals
Travel, Accommodations, Expenses - Hinova Pharmaceuticals
 
Frank Perabo
Employment - Tachyon Therapeutics
Leadership - Tachyon Therapeutics
Stock and Other Ownership Interests - Alnylam; Aurinia Pharmaceuticals; Black Diamond Therapeutics; JNJ; MAIA Biotechnology; Tachyon Therapeutics; Travere Therapeutics; Turning Point Therapeutics
Consulting or Advisory Role - Hinova Pharmaceuticals; Pattern Pharma; Purespring Therapeutics; Radius Health
Patents, Royalties, Other Intellectual Property - KDM4 patents
 
Yuanwei Chen
Employment - Hinova Pharmaceuticals
Leadership - Hinova Pharmaceuticals
Stock and Other Ownership Interests - Hinova Pharmaceuticals
 
Xinghai Li
Employment - Hinova Pharmaceuticals
Stock and Other Ownership Interests - Hinova Pharmaceuticals